Detection of NTRK gene fusions in solid tumors: recommendations from a Latin American group of oncologists and pathologists.
Future Oncol
; 19(40): 2669-2682, 2023 Dec.
Article
em En
| MEDLINE
| ID: mdl-38088163
ABSTRACT
NTRK gene fusions have been detected in more than 25 types of tumors and their prevalence is approximately 0.3% in solid tumors. This low prevalence makes identifying patients who could benefit from TRK inhibitors a considerable challenge. Furthermore, while numerous papers on the evaluation of NTRK fusion genes are available, not all countries have guidelines that are suitable for their setting, as is the case with Latin America. Therefore, a group of oncologists and pathologists from several countries in Latin America (Argentina, Chile, Ecuador, Mexico, Peru and Uruguay) met to discuss and reach consensus on how to identify patients with NTRK gene fusions in solid tumors. To do so, they developed a practical algorithm, considering their specific situation and limitations.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Oncologistas
/
Neoplasias
Limite:
Humans
Idioma:
En
Ano de publicação:
2023
Tipo de documento:
Article